Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor Samples
NCT05171439
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
6
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
Surufatinib
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School